Daniel Lindén
Company: AstraZeneca
Job title: Senior Principal Scientist
Seminars:
Discovering PNPLA3 Antisense Oligonucleotides: Novel Precision Medicine Approach to Treat NASH 11:00 am
• Exploring genetic targets in NASH and the concept of precision medicine for the treatment of the disease • Analyzing the biology of PNPLA3 and mechanistic insights on how a point mutation in the gene associates with NASH • Understanding silencing hepatic PNPLA3 by using a liver targeted GalNAc-conjugated antisense oligonucleotide in NASHRead more
day: Day 2 Stream 1 AM